#$IDYA
Yeah, the Idya cabinet!
November 17, 2026 at 8:02 PM
The target was taito's idya cabinet but I'm not sure what board it uses
November 17, 2026 at 7:54 PM
🤯
Taito IDYA simulator - 3DCG production - 仮想現実遊戯大全
YouTube video by ted909
youtu.be
November 17, 2026 at 10:21 PM
BUY $IDYA (IDYA.O) [FDA] Supporting Evidence For Clearance @ 21:05:03Z
November 16, 2026 at 9:05 PM
#IDYA IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential…

https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-j9nv9004jjro.html?utm_source=stocktitan-bluesky&utm_medium=social
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences (Nasdaq: IDYA) outlined IDE849 registration plans for previously treated neuroendocrine carcinomas following a Type C FDA meeting.The company plans an approximately 90-patient gastroenteropancreatic neuroendocrine carcinoma cohort targeting potential accelerated approval, using confirmed response rate assessed by blinded independent review. A planned randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes would assess progression-free survival for accelerated approval and overall survival for full approval. IDEAYA targets starting both studies and a Phase 3 trial after Imdelltra in extensive-stage small cell lung cancer by year-end 2026.Partner Phase 1 data showed a 52.6% response rate among 19 patients, with 36.8% confirmed responses. In the separate global Phase 1/2 trial, severe treatment-related adverse event rates were 5% and 22.2% at the respective expansion doses.
www.stocktitan.net
November 16, 2026 at 9:05 PM
#$IDYA: Off-exchange shares (share of volume): Nov 12 242,765 (39.4%).
#$IDYA drew $8,024 in options premium: calls $7,584, puts $440 (95% calls).

Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.

Full story at the link.
#darkpool #stocks #stockmarket
IDYA Technical Levels: Chart, Options Flow and Dark Pools Diverge at $31.49
IDYA at $31.49: support $30.45, resistance $32.94; the chart, options flow and dark pools point in different directions.
globaltradersacademy.com
November 13, 2026 at 2:31 AM
$IDYA NEWS Nov 15: IDEAYA nominates IDE101 for CDKN2A-deficient tumors. A potential first-in-class dual CDK inhibitor; IND-enabling studies are underway for an IND filing in the first half of 2027.

Full story (not investment advice): https://www.merlintrader.com/ideaya-biosciences-stock-hub/
November 16, 2026 at 10:47 AM
November 10, 2026 at 10:25 PM
🎣 Histoire naturelle des zoophytes.
Paris, Librairie encyclopédique de Roret, 1843.

[Source]
November 8, 2026 at 7:23 PM
$IDYA: IDEAYA held $1.15B at Sept 30 with funding guided into 2030; the darovasertib NDA was submitted in Q3. Net loss was $125.7M. Not investment advice.

https://www.merlintrader.com/ideaya-biosciences-stock-hub/
November 8, 2026 at 12:20 PM
#$IDYA — IDEAYA will host an Investor R&D Day on Nov 16, 2026 and join two November conferences.

IDYA Stock Hub: IDEAYA Biosciences News, Darovasertib and Precision Oncology
www.merlintrader.com/ideaya-biosc...
November 4, 2026 at 3:16 PM
IDEAYA #$IDYA reported Q3 2026 results and a business update.

$1.15B in cash and securities at Sep 30; runway guidance into 2030 unchanged.

Mon close $31.64: below SMA50, below SMA200, RSI 34.

Hub: www.merlintrader.com/ideaya-biosc...

Not investment advice.
IDYA Stock: IDEAYA News, Darovasertib & Oncology
IDEAYA Biosciences stock news and analysis: darovasertib studies, IDE849 evidence, resources, employee equity awards and clinical and execution risks for IDYA.
www.merlintrader.com
November 3, 2026 at 12:25 PM
🔴 #$IDYA — Clinical Milestone
Phase 3 OptimUM-010 Trial Enrollment Stopped and Trial Closed
Due to site activation and enrollment challenges, IDEAYA stopped enrollment and closed the Phase 3 OptimUM-010 neoadjuvant darovasertib trial. Expected cost savings of $…

https://biostock.app/symbols/IDYA
November 3, 2026 at 2:58 PM
IDEAYA Biosciences $IDYA reported Q3 2026 EPS of -$1.22, missing the -$1.18 estimate by 3.4%. Revenue of $10.2M beat the $7.9M estimate by 30.4%.

https://fundspec.ai/s/IDYA/earnings
Know who reports today, with an AI probability of a beat or a miss.
November 3, 2026 at 11:20 AM
🚨 $IDYA
On November 3, 2026, IDEAYA Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in t...
SEC Filing: IDYA
Click to view the official SEC document.
www.sec.gov
November 3, 2026 at 1:05 PM
#$IDYA weekly close $31.96 (-7.9% w/w), below SMA50 $37.24 / below SMA200 $34.02, RSI 34.6. Range $31.70-$38.56.

IDYA Stock Hub: IDEAYA Biosciences News, Darovasertib and Precision Oncology
www.merlintrader.com/ideaya-biosc...
IDYA Stock: IDEAYA News, Darovasertib & Oncology
IDEAYA Biosciences stock news and analysis: darovasertib studies, IDE849 evidence, resources, employee equity awards and clinical and execution risks for IDYA.
www.merlintrader.com
November 2, 2026 at 11:15 AM
$IDYA slipped 5.3% Monday to $32.88, below both the 50-day SMA ($37.65) and the 200-day ($34.50), near the bottom of its 20-day range ($32.52-$39.39). Daily RSI 36.
$SPY $XBI. Not investment advice.

Bull/bear scenarios on JC Just Charts: https://justcharts.merlintrader.com/#IDYA
October 27, 2026 at 4:54 AM
$IDYA Oct 23, 2026: IDEAYA released updated Phase 1 data from partner Hengrui for IDE849, its DLL3 ADC: in previously treated SCLC, 68.3% response and 14.7 months median overall survival; 17.4 months in second line (51 pts).

https://www.merlintrader.com/ideaya-biosciences-stock-hub/
IDEAYA $IDYA Stock Hub: Darovasertib And $1.24B Of Cash
IDEAYA ($IDYA) hub: the darovasertib registrational path in uveal melanoma, $1.24B of cash, the rising burn, ESMO in October and the risks.
www.merlintrader.com
October 23, 2026 at 12:05 PM
IDEAYA and Servier released updated darovasertib data ahead of ESMO; posters on October 24. $IDYA

https://www.merlintrader.com/ideaya-biosciences-stock-hub/
IDEAYA $IDYA Stock Hub: Darovasertib And $1.24B Of Cash
IDEAYA ($IDYA) hub: the darovasertib registrational path in uveal melanoma, $1.24B of cash, the rising burn, ESMO in October and the risks.
www.merlintrader.com
October 19, 2026 at 4:34 PM
📅 CATALYST REMINDER | #$IDYA
October 23–27, 2026 (conference window) — Oncology Clinical Presentations
ESMO presentations on darovasertib, a Phase 2 combination and IDE849; individual dates not set.
🔗 Full details: www.merlintrader.com/ideaya-biosc...
#IDYA #Biotech #ESMO2026
IDEAYA $IDYA Stock Hub: Darovasertib And $1.24B Of Cash
IDEAYA ($IDYA) hub: the darovasertib registrational path in uveal melanoma, $1.24B of cash, the rising burn, ESMO in October and the risks.
www.merlintrader.com
October 17, 2026 at 6:42 PM